Inducible in vivo genome editing with CRISPR-Cas9.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25690852.
- Also identified by DOI 10.1038/nbt.3155 and PMC identifier 4390466.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CRISPR-Cas9-based genome editing enables the rapid genetic manipulation of any genomic locus without the need for gene targeting by homologous recombination. Here we describe a conditional transgenic approach that allows temporal control of CRISPR-Cas9 activity for inducible genome editing in adult mice. We show that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9(D10A) (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively. Further, we show that this inducible CRISPR (iCRISPR) system can be used effectively to create biallelic mutation in multiple target loci and, thus, provides a flexible and fast platform to study loss-of-function phenotypes in vivo.
Medical subject headings
- CRISPR-Cas Systems
- Clustered Regularly Interspaced Short Palindromic Repeats
- Genome
- Mutagenesis, Site-Directed